Ptc Therapeutics (PTCT) Total Non-Current Liabilities (2012 - 2026)

Ptc Therapeutics' Total Non-Current Liabilities history runs 15 years deep, the most recent figure standing at $3.4 billion for Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 20.07% year-over-year to $3.4 billion; the TTM figure through Jun 2026 stood at $3.4 billion (up 20.07% YoY), while the FY2025 annual figure was $3.1 billion, up 11.1% from the prior year.
• Total Non-Current Liabilities for Q2 2026 stood at $3.4 billion, up from $3.0 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $3.4 billion in Q2 2026, with the low at $1.6 billion in Q3 2022.
• The 5-year median for Total Non-Current Liabilities is $2.7 billion (2023), against an average of $2.5 billion.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities soared 52.95% in 2024, then retreated 2.7% in 2025.
• Ptc Therapeutics' Total Non-Current Liabilities stood at $1.9 billion in 2022, then jumped by 41.79% to $2.7 billion in 2023, then advanced by 3.87% to $2.8 billion in 2024, then advanced by 11.1% to $3.1 billion in 2025, then climbed by 10.06% to $3.4 billion in 2026.
• Business Quant data shows PTCT's Total Non-Current Liabilities at $3.4 billion in Q2 2026, $3.0 billion in Q1 2026, and $3.1 billion in Q4 2025.